iStock-1079939122_ajustes (5).jpg

Almirall News Centre

Header

Latest news

13 March 2024

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

19 February 2024

Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology

19 February 2024

Almirall’s Full-Year 2023 Results: Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business

Useful information

About us

Everything you need to know about Almirall.

Atopic dermatitis press kit

Information about the disease and our latest biologic treatment.

Multimedia

Our brand in pictures and videos.

Go to multimedia

Media contact

Almirall Media Relations

Corporate Communications

corporate.communication@almirall.com

T+ 34 932 913 000